
Opinion|Videos|September 25, 2024
Optimal Timing and Frequency of Imagining Agents Used in the Detection and Characterization of Oligometastatic Prostate Cancer
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Jaideep Sohi, MD, and Jeremie Calais, MD, conduct a comparative assessment of gallium-based and non-gallium-based imaging agents for their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do you determine the optimal timing and frequency of imaging studies using specific agents to monitor oligometastatic disease progression in prostate cancer patients?
Advertisement
Related to this article

Emerging CT research suggests that the plexus pancreaticus capitalis 2 (PPC2) pathway or a mass with stranding morphology may significantly increase mortality risk in patients with pancreatic cancer and extra-pancreatic nerve plexus invasion (EPNI).

In the second of a two-part podcast episode, Kalpana Kanal, PhD, and Mahadevappa Mahesh, PhD, discussed the possible impact of new research showing significant declines in CT radiation dosing over the past decade, future research directions and the potential for indication-based diagnostic reference levels (DRLs) in the future.

Emerging research suggests that the benefits of photon-counting CT may be more pronounced in patients with obesity.

Catch up on the most well-viewed radiology video interviews from Diagnostic Imaging in September 2026.

In the first of a two-part podcast episode, Kalpana Kanal, PhD, and Mahadevappa Mahesh, PhD, reviewed key findings from a study examining CT radiation dosing over the past decade and shared insights from their experience for ensuring optimal radiation dosing for CT scans.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Key Features with EPNI on CT May More than Double Mortality Risk in Pancreatic Cancer
2
Top Five Radiology Content in October 2026
3
Webinar: Current Perspectives and Recommendations on Ensuring Cybersecurity
4
FDA Clears AI-Enabled Chest CT Software for Aortic Analysis
5



